Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232738 · ClinicalTrials.gov registry record · Phase 2
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Yunxia Wang, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 10
- Study locations
NCT01232738 is a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by Yunxia Wang, MD. The registered enrollment target is 36 participants, below the 259-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (86% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT01232738, a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by Yunxia Wang, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 10
- Study locations
Study Summary
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS. Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means that the nervous system may be protected against weakening. It is known that rasagiline has possible neuroprotective characteristics and it is approved for use for patients with another disorder, the effectiveness of rasagiline for patients with ALS has not been tested.
Conditions Studied
Interventions
- DRUG rasagiline
Study Locations (10)
Arizona
- Phoenix Neurological Institute - Phoenix
California
- California Pacific Medical Center - San Francisco
Iowa
- University of Iowa - Iowa City
Kansas
- University Of Kansas Medical Center - Kansas City
Minnesota
- University of Minnesota - Minneapolis
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- University of Tennessee - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232738
The ClinicalTrials.gov registry entry for NCT01232738 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (86% lower). The listed sponsor is Yunxia Wang, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 1 intervention - of which rasagiline is the first listed.
NCT01232738 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Arizona, California, Iowa.
Frequently Asked Questions
What is clinical trial NCT01232738 about?
NCT01232738 is a clinical study titled "Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)". ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS. Rasagili...
What is the current status of trial NCT01232738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2011-12. Estimated completion is 2013-05.
What conditions does trial NCT01232738 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT01232738?
The interventions under investigation include: rasagiline (DRUG).
Who is sponsoring clinical trial NCT01232738?
This trial is sponsored by Yunxia Wang, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01232738 being conducted?
This trial has 10 study locations across Arizona, California, Iowa, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 2
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.